How profitable is Sarepta Therapeutics Inc. (SRPT)?

In FY 2025 (10-K), SRPT converted $1.9B of revenue into a 98.6% gross margin, 0% operating margin, and $0 in free cash flow (0% FCF margin).

Stock Ratings / Health Care / SRPT / financials

SLS (38) XERS (64) BRVE (46) TRVI (30) ⌘ Pro Terminal →

Sarepta Therapeutics Inc. (SRPT) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

Q: Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?

SRPT last traded at $18.32 (-1.61% on volume of 1,159,406 shares), positioning the stock -4.88% below its 50-day simple moving average ($19.26) and -2.03% below its 200-day simple moving average ($18.70). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 36.4% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($16.34 to $20.30).

$18.32 -1.61% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $18.23

Sarepta Therapeutics Inc. (SRPT) carries a Roarable Rating of E (Strong Sell) with 27/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $1.97B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on SRPT Below — or Connect Your Own ChatGPT / Claude

🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

▼

As of 2026-11-03, Sarepta Therapeutics Inc. (NASDAQ: SRPT) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 27/100 at a spot price of $18.32 (-1.61% 1D, market cap $1.97B). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 8/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 3/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, SRPT ranks #879 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief

🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does SRPT compare to SLS and XERS in the Health Care sector?

▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), SRPT carries a Roarable E (27/100 RQD), trailing P/E of N/A, gross margin of 96.0%, and ROIC of -35.0%. By comparison, SLS (SELLAS Life Sciences Group Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -21.8%, cap $1.95B) and XERS (Xeris Biopharma Holdings Inc.) posts a C grade (64/100 RQD, P/E N/A, ROIC 16.0%, cap $1.95B). Among the 5-stock peer group, SRPT leads on earnings multiple (N/A) while XERS leads on capital efficiency (16.0% ROIC).

✓ Pre-computed one-to-many AI Quant brief

🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for SRPT?

▼

Per SRPT's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000873303), Sarepta Therapeutics Inc. generated $1.86B in revenue (+4.3% YoY), -$713.4M in net income, and -$307.5M in free cash flow against $3.35B in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief

🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $18.23 (-0.48%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (27/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERRED ALERT • E

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk E

Each axis scored 0–20

12M PRICE TARGET CONE-14% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for SRPT)Realized 20D OHLCV Swing Band: ±10.8%

Deterministic 5-Pillar Attribution (27/100 Composite)

🔍 WHY SRPT SCORES 27/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+8/20 pts (30% of score)

20D Institutional Volume Accumulation (±10.8% realized swing band)

▲ #2 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (30% of score)

Altman Z-Score 0.20 (DISTRESS RISK (<1.8)) • Piotroski F-Score 4/9

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade E$16.51+16.1% Next Q

Q2 (-2Q)

Grade E$19.17-1.5% Next Q

Q3 (-1Q)

Grade E$18.89-3% Next Q

Current

Grade E$18.32-10.3% Hist 90D α

Trajectory: E (19) → E (27)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a SRPT Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While SRPT currently carries a cautious 27/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.26) and Max Pain ($19.24) forces dealer call-delta covering toward $25.91.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $SRPT• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “SRPT Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 27%NO 73%Trade / Inspect Odds →

VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • FY 2025 (10-K)

How SRPT Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$0 (0% FCF Margin)

Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory

■ Revenue■ Net Profit■ Free Cash Flow

FY23

Rev $1.14B

FY24

Rev $1.79B

FY25

Rev $1.86B

Fiscal Year	Revenue	Gross Margin	Op Margin	Net Profit	Free Cash Flow	ROIC %
FY 2025	$1.86B	98%	-37.5%	-$713.4M	-$307.5M	-45%
FY 2024	$1.79B	92%	12.2%	$235.2M	-$342.7M	40.6%
FY 2023	$1.14B	92%	-23.4%	-$536.0M	-$501.0M	-35%

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring SRPT)

✓Walkthrough of SRPT's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

SRPT // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -16.88%▲ ASCENDING CHANNEL

2026-11-03O $19.23H $19.23L $18.32C $18.32VOL 1.32M

RES: $26.64SUP: $16.81SMA50: $19.26SMA200: $18.70

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

SRPT Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 SRPT Butterfly Map → + Track SRPT →

Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle

8.0%/yr Implied 5Y Growth

vs. +4.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on SRPT today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for SRPT. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for SRPT today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (SRPT)

Health Care Rank #879 of 1015 ⚔️ SLS vs SRPT Full Matrix →

1. Head-to-Head Health Care Peer Comparison (SRPT vs. SLS, XERS, BRVE, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Sarepta Therapeutics Inc. (SRPT) ranks #879 by composite RQD confidence (27/100, grade E) and #257 by equity capitalization ($1.97B). Within this direct 5-issuer industry benchmark cohort, SRPT leads on earnings valuation at N/A trailing P/E, while XERS leads on capital efficiency and profitability with 16.0% ROIC and — gross margin. XERS currently holds the highest overall quantitative score in the immediate peer group at 64/100 (C) compared with SRPT at 27/100 (E).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
SRPT ACTIVE Sarepta Therapeutics Inc.	E	27/100	—	96.0%	-35.0%	-1.61%	$1.97B	Benchmark Subject
SLS SELLAS Life Sciences Group Inc.	D-	38/100	—	—	-21.8%	-11.67%	$1.95B	/sls-vs-srpt →
XERS Xeris Biopharma Holdings Inc.	C	64/100	—	—	16.0%	-5.04%	$1.95B	/xers-vs-srpt →
BRVE Braveheart Bio Inc.	D	46/100	—	—	—	-2.18%	$1.94B	/brve-vs-srpt →
TRVI Trevi Therapeutics Inc.	E	30/100	—	—	-23.7%	+0.52%	$1.93B	/trvi-vs-srpt →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000873303 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported GAAP revenue of $1.86B (+4.3% vs. FY2024 revenue of $1.79B , and +62.8% cumulative change since FY2023) , GAAP net income of -$713.4M, operating cash flow of -$205.5M, and free cash flow of -$307.5M (+10.3% YoY). On the balance sheet, SRPT closed FY2025 with $3.35B in total assets against $0 in total debt (Altman Z-Score: 0.20, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$1.86B	-$713.4M	-$205.5M	-$307.5M	$3.35B	—
FY2024 (FY)	2024-12-31	$1.79B	$235.2M	-$205.8M	-$342.7M	$3.96B	—
FY2023 (FY)	2023-12-31	$1.14B	-$536.0M	-$501.0M	-$501.0M	—	—

3. SRPT Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is SRPT stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

How does SRPT compare to SLS and XERS in the Health Care sector?

What are the biggest fundamental strengths and SEC risk factors for SRPT?

Where is SRPT trading relative to its 50-day, 200-day, and 52-week technical levels?

SRPT last traded at $18.32 (-1.61% on volume of 1,159,406 shares), positioning the stock -4.88% below its 50-day simple moving average ($19.26) and -2.03% below its 200-day simple moving average ($18.70). Across its 52-week range of $14.68 to $24.68, SRPT sits at the 36.4% percentile with a 14-day RSI of 50.7 (NEUTRAL RANGE) and an implied next-earnings move of ±10.8% ($16.34 to $20.30).

Direct Sub-Reports: SRPT RQD Cockpit SRPT 12M Forecast SRPT Earnings & Move SRPT Dividends & DRIP SRPT Insiders & 13F SRPT Whale Options SRPT Profit Sankey SRPT News & Why

ROARABLE RATING BRIEF • RQD 27/100 (E) ✓ SEC XBRL & RQD VERIFIED

SRPT — Sarepta Therapeutics Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit

Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Sarepta Therapeutics Inc. (SRPT) earns a live Roarable RQD composite score of 27/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $18.32 (-1.61% 1D, market capitalization $1.97B).

Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 96.0%, operating margin of -37.5%, and free cash flow yield of -15.14%.
Whale 13F & Options Flow (8/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
Macro Regime Fit (3/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.20, Piotroski F-Score of 4/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Sarepta Therapeutics Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in the Biotechnology: Pharmaceutical Preparations industry. The profile does not describe its products, customers, or revenue model. Reported revenue was $1.86B for FY 2025 and $1.79B for FY 2024, with a gross margin of 96% per the market data.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Sarepta Therapeutics Inc. (SRPT) reported $1.86B in annual revenue (up from $1.79B in FY2024, +4.3% YoY) and -$713.4M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($1.14B revenue, -$536.0M net income) through FY2025, SRPT scaled operating cash flow to -$205.5M and free cash flow to -$307.5M, backed by $3.35B in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

🐂 Primary Bull Case (E • RQD 27/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -15.14% and institutional whale pillar of 8/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 8/20, sustained execution supports upside toward the upper end of the $14.68 – $24.68 52-week range.
🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -37.5% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Operating in Biotechnology: Pharmaceutical Preparations (Health Care), SRPT carries a macro regime beta of 1.00 and gross margin of 96.0%.

Key Question #1: Can SRPT sustain or expand its -37.5% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
Key Question #2: Following FY2025 revenue of $1.86B and free cash flow of -$307.5M, how will capital allocation balance growth reinvestment against $0 in total debt?
Key Question #3: How sensitive is SRPT's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

SRPT Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Sarepta Therapeutics Inc. (SRPT) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to SRPT Debate Forum (3) ↓

🟡 MARKET WIRE Yahoo Finance • 22h ago

Jim Cramer Explains His Hesitation Over Sarepta (SRPT) Therapeutics

Yahoo Finance report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Sarepta Therapeutics • 1d ago

Sarepta Therapeutics Presents New Preclinical Data Demonstrating Robust Knockdown of Pathogenic DMPK RNA in the Nucleus with SRP-1003 in DM1 at 2026 Oligonucleotide Therapeutics Society Annual Meeting

Sarepta Therapeutics report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟢 CATALYST Stocktwits • 1d ago

This Analyst Sees 34% Upside For SRPT Stock — Here's Why They Expect A Sustained Rally Next

Stocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE TradingView • 1d ago

Sarepta Therapeutics, Inc. News — BMV:SRPT

TradingView report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Yahoo! Finance Canada • 1d ago

Sarepta Therapeutics, Inc. (SRPT) Stock Price, News, Quote & History

Yahoo! Finance Canada report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Simply Wall St • 1d ago

Two Stories Ran On Sarepta Therapeutics. Only One Held Up

Simply Wall St report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🟡 MARKET WIRE Business Wire • 1d ago

Sarepta Therapeutics Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Sarepta Therapeutics, Inc. - SRPT

Business Wire report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔴 RISK WATCH Stocktwits • 1d ago

SRPT Stock Snaps Hot Winning Streak Ahead Of Q4 Print — What Bear Positioning And Big Money Are Signaling

Stocktwits report covering Sarepta Therapeutics Inc. (SRPT) market action, institutional positioning, and fundamental catalysts.

Read Full Source ↗

🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

SRPT Bull vs. Bear Conversation Board — What's Your Call at $18.32?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON SRPT 🐻 33% BEARISH CONVICTION

MA MacroHawk_NYC RQD DEBATE OPENER • Cross-Asset Macro Desk 🐂 BULLISH 🎯 Target: $22.16 (+19.0%)

📌 Pinned Debate

Institutional flow is scored at 11/20, the strongest pillar relative to weight, and the 96% gross margin indicates high revenue-level e

Don't sleep on SRPT's setup in Health Care. Institutional flow is scored at 11/20, the strongest pillar relative to weight, and the 96% gross margin indicates high revenue-level economics.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (27/100) backs up the fundamental quality.

SectorRotator 🐂 BULL

@MacroHawk_NYC Agree on the RQD 27/100 quality, though with 1.0 beta I'm scaling in with half-size at $18.62 and keeping dry powder in case we test $17.32.

SK SkepticalCFA RQD DEBATE OPENER • Fundamental Contrarian 🐻 BEARISH 🎯 Target: $14.90 (-20.0%)

Spot @ $18.62

Altman Z of 0.2, Piotroski F of 4/9, ROIC of -35%, and FCF yield of -15.14% signal a fragile balance sheet and cash-burning operations.

Fading this rally in SRPT at $18.62. Altman Z of 0.2, Piotroski F of 4/9, ROIC of -35%, and FCF yield of -15.14% signal a fragile balance sheet and cash-burning operations.. With a beta of 1.0 and the stock sitting at $18.62 (52-wk range $14.68–$24.68), the easy multiple expansion is already priced in.